HIF-1α Regulation for Ischemic Stroke Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to effectively regulate the balance between adaptive and pathological transcription in response to hypoxia, particularly in conditions like ischemic stroke, where HIF-1α plays a complex role, and the molecular basis of HIF-1α transcriptional switching behavior remains incompletely defined.
Innovation Solution
Modulating MKP-1's activity towards HIF-1α or directly regulating the machinery involved in HIF-1α cleavage as therapeutic strategies for stroke and associated disorders, by administering compounds that reduce HIF-1α inactivation or alter its activity in cells, thereby treating hypoxic conditions and tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If HIF-1α is stabilized to enhance adaptive transcription, then cellular survival is improved, but pathological transcription and delayed neuronal apoptosis are worsened
Solution Approach 1:
The patent applies local quality by developing compounds that selectively modulate HIF-1α activity in specific contexts - stabilizing it during acute ischemia to promote survival, while preventing its pathological activation during prolonged stress. The compounds target specific cellular compartments or interaction interfaces to achieve spatially differentiated regulation of HIF-1α function.
Solution Approach 2:
The invention implements dynamics by creating compounds that enable temporal regulation of HIF-1α - allowing it to be stabilized during the acute phase of ischemia for adaptive responses, while facilitating its degradation or inactivation during prolonged stress to prevent pathological outcomes. This dynamic control transforms HIF-1α from a static target into a temporally regulated therapeutic switch.
2Productivity
If HIF-1α transcriptional activity is enhanced, then adaptive gene expression is improved, but pro-apoptotic gene activation is worsened
Solution Approach 1:
The patent applies segmentation by developing compounds that target specific HIF-1α transactivation domains or protein-protein interaction interfaces, thereby selectively enhancing adaptive gene expression while leaving pro-apoptotic pathways unaffected. This modular approach allows independent control of different HIF-1α functional domains.
Solution Approach 2:
The invention uses intermediary compounds that bind to HIF-1α or its interaction partners to modulate its transcriptional activity. These small molecule intermediaries act as molecular switches that can promote or inhibit HIF-1α-dependent gene expression in a selective manner, bridging the gap between HIF-1α stabilization and pathological outcomes.
3Object-generated harmful factors
If HIF-1α is inhibited to prevent cell death, then pathological transcription is reduced, but adaptive transcription and cell survival are worsened
Solution Approach 1:
The patent applies preliminary anti-action by developing compounds that preemptively block HIF-1α's pathological transactivation potential before it can drive pro-apoptotic gene expression, while preserving its ability to activate adaptive genes. This preventive approach stops harmful transcriptional switching before it occurs.
Solution Approach 2:
The invention inverts the conventional approach by instead of globally inhibiting or stabilizing HIF-1α, using compounds that selectively reverse HIF-1α's transcriptional preferences - flipping its activity from pro-apoptotic to pro-survival gene expression through targeted modulation of its transactivation domain or co-factor interactions.
Data Source
AI summary
The present invention relates to a method of treating a patient for a condition where blood flow to a tissue or organ is interrupted. This method involves administering to a patient with a hypoxic condition where blood flow to a tissue or organ is interrupted, or at risk thereof, a compound that reduces the rate of HIF-1α inactivation in cells affected by the condition, thereby treating the patient for the condition. Also disclosed is a method of treating a tumor in a patient. In addition, the present invention relates to methods of identifying compounds as candidate drugs for treatment of hypoxic conditions and for treating tumors in a subject.